Linezolid: a review of safety and tolerability (Q37600404)

21 August 2017

1 reference

title

Linezolid: a review of safety and tolerability (English)

1 reference

21 August 2017

1 reference

Donald C Vinh

1

1 reference

21 August 2017

Ethan Rubinstein

series ordinal

2

1 reference

21 August 2017

publication date

1 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

59 Suppl 1

1 reference

21 August 2017

page(s)

S59-74

1 reference

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid for the treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Clinical experience with linezolid for the treatment of nocardia infection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Activity of linezolid against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Anaerobic sepsis due to multidrug-resistant Bacteroides fragilis: microbiological cure and clinical response with linezolid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Peripheral neuropathy associated with prolonged use of linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-induced neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-associated peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid therapy for orthopedic infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Severe sensory neuropathy associated with long-term linezolid use.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-associated toxic optic neuropathy: a report of 2 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Multi-system Infection with Nocardia farcinica-therapy with linezolid and minocycline

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Severe bilateral optic neuritis associated with prolonged linezolid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Optic neuropathy associated with linezolid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid induced toxic optic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-induced inhibition of mitochondrial protein synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-induced optic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-associated toxic optic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Chloramphenicol optic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

A review of linezolid: the first oxazolidinone antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-induced lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Hematologic effects of linezolid: summary of clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Safety and tolerability of linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Thrombocytopenia associated with linezolid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Thrombocytopenia secondary to linezolid administration: what is the risk?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Mechanisms for linezolid-induced anemia and thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Hypersegmented megakaryocytes and megakaryocytes with multiple separate nuclei in dogs treated with PNU-100592, an oxazolidinone antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid and reversible myelosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid and reversible myelosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-induced pure red blood cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-induced dyserythropoiesis: chloramphenicol toxicity revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Hematologic features and clinical course of an infant with Pearson syndrome caused by a novel deletion of mitochondrial DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-induced pancytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Challenges with linezolid therapy and reversible pancytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Probable linezolid-induced pancytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Definition of clinically relevant lactic acidosis in patients with internal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Serotonin Syndrome after Concomitant Treatment with Linezolid and Citalopram

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid use associated with lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Mitochondrial toxicity associated with linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Lactic acidosis after treatment with linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Early linezolid-associated lactic acidosis in a patient treated for tuberculous spondylodiscitis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid and rifampin: Drug interaction contrary to expectations?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Treatment with linezolid and rifampicin for 18 months for recurrent infection of a megaprosthesis in a patient with Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Successful treatment with linezolid and rifampicin of meningitis due to methicillin-resistant Staphylococcus epidermidis refractory to vancomycin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

The Serotonin Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Serotonin syndrome and linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Serotonin syndrome and linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid and serotonin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Serotonin syndrome due to co-administration of linezolid and venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Serotonin toxicity associated with concomitant use of linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Acute delirium associated with combined diphenhydramine and linezolid use.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Serotonin syndrome after concomitant treatment with linezolid and meperidine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

A method for estimating the probability of adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Safety and tolerability of linezolid in children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Use of linezolid in children. Introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Hematologic effects of linezolid in young children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Tooth discoloration after treatment with linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

Linezolid-induced bradycardia: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

1 reference

7 January 2021

Mitochondrial respiratory chain disorders I: mitochondrial DNA defects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960009-8

7 January 2021

10.1016/S0163-4453(09)60009-8

Identifiers

DOI

1 reference

21 August 2017

1 reference